Rankings
▼
Calendar
ALNY Q4 2016 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
Q4 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$17M
Gross Profit
$17M
100.0% margin
Operating Income
-$115M
-661.4% margin
Net Income
-$113M
-647.0% margin
EPS (Diluted)
$-1.32
QoQ Revenue Growth
+27.9%
Cash Flow
Operating Cash Flow
-$78M
Free Cash Flow
-$98M
Stock-Based Comp.
$21M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$343M
Stockholders' Equity
$920M
Cash & Equivalents
$194M
← FY 2016
All Quarters
Q1 2017 →
